Table 3

Characteristics of the study population (n=1,096)
Factor/strata n %
Female gender 372 33.9%
Non Italian nationality 284 25.9%
Risk group Heterosexual 421 38.4%
Homo/bisexual 213 19.4%
IDU 199 18.2%
Other/unknown 263 24.0%
CDC stage A 495 45.2%
B 229 20.9%
C 372 33.9%
HIV subtype B 284 25.9%
28_BF 84 7.7%
17_BF 48 4.4%
F1 27 2.5%
Other 48 4.4%
Unknown 557 50.8%
First-line anti-HIV therapy (encoding i) 2NRTI+1NNRTI 227 20.7%
2NRTI+1PI 214 19.5%
2NRTI+1PI/r 426 38.9%
Other combination 229 20.9%
First-line anti-HIV therapy (encoding iv) Truvada® + Sustiva® 47 4.3%
Atripla® 14 1.2%
Reyataz® ± ritonavir + backbone 22 2.0%
Kaletra® + backbone 389 35.5%
Any other NRTI+NNRTI 165 15.0%
Any other NRTI+PI 221 20.2%
Any other NRTI+PI/r 18 1.6%
Other combinations 220 20.1%
Non-anti-HIV therapies (concomitant) anti-TB 140 12.8%
anti-PCP 425 38.8%
anti-HCV 14 1.3%
other antibiotics 194 17.7%
other drugs 238 21.7%
HBsAg negative 978 89.2%
positive 56 5.1%
unknown 62 5.7%
HCVAb negative 771 70.3%
positive 247 22.5%
unknown 78 7.1%
Discontinuation/switch for adverse events 302 27.5%
Discontinuation/switch for other causes 618 56.4%
Non-discontinued first-line anti-HIV therapies 176 16.1%
Years 1988-1993 1994-1998 1999-2004 2005-2010
Discontinuation/switch for adverse events 17 92 108 85
Patients starting a first-line ART 88 229 349 430
PYFU 282.06 350.26 724.36 504.58
Numerical markers Median IQR
Calendar year 2003 1998-2006
Days on first-line anti-HIV therapy 379 131-855
Age (years) 36 31-43
Years from the first HIV positive test 0.5 0.1-3.4
HIV-RNA Log10 copies/mL 4.8 4.7-5.2
CD4+ T cells/mm3 194 122-233

Prosperi et al.

Prosperi et al. BMC Infectious Diseases 2012 12:296   doi:10.1186/1471-2334-12-296

Open Data